Literature DB >> 29105968

Reports of adverse health effects related to synthetic cannabinoid use in New York State.

Eleni A Papadopoulos1, Karen R Cummings1, Jeanna M Marraffa2, Kenneth M Aldous1, Lingyun Li1, Nina Ahmad1.   

Abstract

BACKGROUND/
OBJECTIVES: We assessed synthetic cannabinoid (SC) outbreaks from 2011-2012 and 2015.
METHODS: The National Poison Data System was utilized to collect reports of SC adverse effects in New York State from 2011-2012 and 2015 (N = 713).
RESULTS: Cases from 2015 were more likely to be admitted to intensive care units and had different symptoms than those in 2011-2012. We identified two new SC structural classes from 2015 samples. DISCUSSION/
CONCLUSIONS: The 2015 outbreak was associated with more severe SC-related illnesses than in 2011-2012. SCIENTIFIC SIGNIFICANCE: New SC compounds may pose a different or more severe risk than those previously identified. (Am J Addict 2017;26:772-775).
© 2017 American Academy of Addiction Psychiatry.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29105968     DOI: 10.1111/ajad.12636

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  2 in total

1.  Coma, Seizures, Atrioventricular Block, and Hypoglycemia in an ADB-FUBINACA Body-Packer.

Authors:  Nicholas Nacca; Rachel Schult; Robert Loflin; Adam Weltler; Rachel Gorodetsky; Sherri Kacinko; Jeffery Moran; Alex Krotulski; Timothy Wiegand
Journal:  J Emerg Med       Date:  2018-10-05       Impact factor: 1.484

2.  Synthesis and pharmacological evaluation of newly detected synthetic cannabinoid receptor agonists AB-4CN-BUTICA, MMB-4CN-BUTINACA, MDMB-4F-BUTICA, MDMB-4F-BUTINACA and their analogs.

Authors:  Eric Sparkes; Rochelle Boyd; Shuli Chen; Jack W Markham; Jia Lin Luo; Tahira Foyzun; Humayra Zaman; Charlotte Fletcher; Ross Ellison; Iain S McGregor; Marina J Santiago; Felcia Lai; Roy R Gerona; Mark Connor; David E Hibbs; Elizabeth A Cairns; Michelle Glass; Adam Ametovski; Samuel D Banister
Journal:  Front Psychiatry       Date:  2022-09-28       Impact factor: 5.435

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.